Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib vs Chemotherapy in Recurrent Clear Cell Carcinoma of the Ovary or Endometrium
NCT02866370Phase 2Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Apr 2015
- Primary completion
- Mar 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in ovarian clear cell carcinoma (OCCC), endometrial clear cell carcinoma (ECC), sponsored by NHS Greater Glasgow and Clyde. Status: unknown.
02
Drugs
nintedanib
03
Conditions
ovarian clear cell carcinoma (OCCC)endometrial clear cell carcinoma (ECC)
Beyond the preview
Go deeper on NCT02866370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02866370.